Northwest Biotherapeutics (NWBO) Net Margin (2010 - 2026)
Northwest Biotherapeutics' (NWBO) quarterly Net Margin came in at 688.26% in Q1 2026, up 454054.0% year-on-year from N/an in Q1 2025, and down 469.71% quarter-over-quarter from 186.16% in Q4 2025.
Northwest Biotherapeutics (NWBO) Net Margin (2010 - 2026) Analysis & Trends
Northwest Biotherapeutics' Net Margin history runs 17 years deep, the most recent figure standing at 688.26% for Q1 2026.
- On a quarterly basis, Net Margin rose 454054.0% year-over-year to 688.26% in Q1 2026; TTM through Mar 2026 was 3023.98%, a 280901.0% increase from a year earlier, with the FY2025 full-year figure at 4461.32%, up 170308.0% from the prior year.
- Net Margin slipped to 688.26% in Q1 2026 per NWBO's latest filing, from 186.16% in the prior quarter.
- Across five years, Net Margin topped out at 186.16% in Q4 2025 and bottomed at 15947.57% in Q3 2022.
- The 5-year median for Net Margin is 5463.87% (2024), against an average of 6341.24%.
- Across the five-year window, Net Margin sank 1720757 bps in 2022 and surged 1252209 bps in 2025, its largest moves.
- Year by year, Net Margin stood at 4740.03% in 2022, then soared by 32 bps to 3217.53% in 2023, then slumped by 283 bps to 12335.93% in 2024, then surged by 102 bps to 186.16% in 2025, then slumped by 470 bps to 688.26% in 2026.
- Per Business Quant, the three latest NWBO Net Margin figures stand at 688.26% (Q1 2026), 186.16% (Q4 2025), and 13591.0% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Northwest Biotherapeutics | 253,653.43 | -1.53 Mn | - | -688.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -688.26% |
| Dec 31, 2025 | 186.16% |
| Sep 30, 2025 | -13,591.00% |
| Jun 30, 2025 | -12,166.41% |
| Mar 31, 2025 | -5,228.80% |
| Dec 31, 2024 | -12,335.93% |
| Sep 30, 2024 | -5,463.87% |
| Jun 30, 2024 | -3,590.20% |
| Mar 31, 2024 | -6,647.89% |
| Dec 31, 2023 | -3,217.53% |
| Sep 30, 2023 | -5,921.43% |
| Jun 30, 2023 | -7,446.27% |
| Mar 31, 2023 | -1,255.34% |
| Dec 31, 2022 | -4,740.03% |
| Sep 30, 2022 | -15,947.57% |
| Jun 30, 2022 | -6,219.71% |
| Mar 31, 2022 | -3,527.05% |
| Sep 30, 2021 | 1,260.00% |
| Jun 30, 2021 | 1,060.10% |
| Mar 31, 2021 | -1,725.10% |